Literature DB >> 18245083

I1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A.

She Chen1, Bin Li, Inge Grundke-Iqbal, Khalid Iqbal.   

Abstract

In Alzheimer disease (AD) brain, the level of I (1)(PP2A), a 249-amino acid long endogenous inhibitor of protein phosphatase 2A (PP2A), is increased, the activity of the phosphatase is decreased, and the microtubule-associated protein Tau is abnormally hyperphosphorylated. However, little is known about the detailed regulatory mechanism by which PP2A activity is inhibited by I (1)(PP2A) and the consequent events in mammalian cells. In this study, we found that both I (1)(PP2A) and its N-terminal half I (1)(PP2A(1-120)), but neither I (1)(PP2A(1-163)) nor I (1)(PP2A(164-249)), inhibited PP2A activity in vitro, suggesting an autoinhibition by amino acid residues 121-163 and its neutralization by the C-terminal region. Furthermore, transfection of NIH3T3 cells produced a dose-dependent inhibition of PP2A activity by I (1)(PP2A)(1). I (PP2A) and PP2A were found to colocalize in PC12 cells. I (1)(PP2A) could only interact with the catalytic subunit of PP2A (PP2Ac) and had no interaction with the regulatory subunits of PP2A (PP2A-A or PP2A-B) using a glutathione S-transferase-pulldown assay. The interaction was further confirmed by coimmunoprecipitation of I (1)(PP2A) and PP2Ac from lysates of transiently transfected NIH3T3 cells. The N-terminal isotype specific region of I (1)(PP2A) was required for its association with PP2Ac as well as PP2A inhibition. In addition, the phosphorylation of Tau was significantly increased in PC12/Tau441 cells transiently transfected with full-length I (1)(PP2A) and with PP2Ac-interacting I (1)(PP2A) deletion mutant 1-120 (I (1)(PP2A)DeltaC2). Double immunofluorescence staining showed that I (1)(PP2A) and I (1)(PP2A)DeltaC2 increased Tau phosphorylation and impaired the microtubule network and neurite outgrowth in PC12 cells treated with nerve growth factor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245083      PMCID: PMC2447634          DOI: 10.1074/jbc.M709852200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

1.  Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain.

Authors:  Shi Jie Liu; Jia Yu Zhang; Hong Lian Li; Zheng Yu Fang; Qun Wang; Heng Mei Deng; Cheng Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal; Jian Zhi Wang
Journal:  J Biol Chem       Date:  2004-09-15       Impact factor: 5.157

Review 2.  Tau pathology in Alzheimer disease and other tauopathies.

Authors:  Khalid Iqbal; Alejandra del C Alonso; She Chen; M Omar Chohan; Ezzat El-Akkad; Cheng-Xin Gong; Sabiha Khatoon; Bin Li; Fei Liu; Abdur Rahman; Hitoshi Tanimukai; Inge Grundke-Iqbal
Journal:  Biochim Biophys Acta       Date:  2005-01-03

3.  The regulation of phosphorylation of tau in SY5Y neuroblastoma cells: the role of protein phosphatases.

Authors:  T Tanaka; J Zhong; K Iqbal; E Trenkner; I Grundke-Iqbal
Journal:  FEBS Lett       Date:  1998-04-17       Impact factor: 4.124

4.  Biochemical characterization of mapmodulin, a protein that binds microtubule-associated proteins.

Authors:  N Ulitzur; C Rancaño; S R Pfeffer
Journal:  J Biol Chem       Date:  1997-11-28       Impact factor: 5.157

5.  Expression analysis and chromosomal mapping of a novel human gene, APRIL, encoding an acidic protein rich in leucines.

Authors:  M Mencinger; I Panagopoulos; J A Contreras; F Mitelman; P Aman
Journal:  Biochim Biophys Acta       Date:  1998-01-21

6.  Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau.

Authors:  A D Alonso; I Grundke-Iqbal; H S Barra; K Iqbal
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-07       Impact factor: 11.205

Review 7.  REVIEW: tau protein pathology in Alzheimer's disease and related disorders.

Authors:  M Tolnay; A Probst
Journal:  Neuropathol Appl Neurobiol       Date:  1999-06       Impact factor: 8.090

8.  Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies.

Authors:  E Sontag; V Nunbhakdi-Craig; G Lee; R Brandt; C Kamibayashi; J Kuret; C L White; M C Mumby; G S Bloom
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

9.  Inhibitors of protein phosphatase-2A from human brain structures, immunocytological localization and activities towards dephosphorylation of the Alzheimer type hyperphosphorylated tau.

Authors:  Ichiro Tsujio; Tanweer Zaidi; Jiliu Xu; Leszek Kotula; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  FEBS Lett       Date:  2005-01-17       Impact factor: 4.124

Review 10.  Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles.

Authors:  K Iqbal; A C Alonso; C X Gong; S Khatoon; J J Pei; J Z Wang; I Grundke-Iqbal
Journal:  J Neural Transm Suppl       Date:  1998
View more
  26 in total

1.  Cracking the ANP32 whips: important functions, unequal requirement, and hints at disease implications.

Authors:  Patrick T Reilly; Yun Yu; Ali Hamiche; Lishun Wang
Journal:  Bioessays       Date:  2014-08-25       Impact factor: 4.345

2.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

3.  ANP32A and ANP32B are key factors in the Rev-dependent CRM1 pathway for nuclear export of HIV-1 unspliced mRNA.

Authors:  Yujie Wang; Haili Zhang; Lei Na; Cheng Du; Zhenyu Zhang; Yong-Hui Zheng; Xiaojun Wang
Journal:  J Biol Chem       Date:  2019-08-23       Impact factor: 5.157

4.  Cytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces Alzheimer-like abnormal hyperphosphorylation of Tau.

Authors:  Mohammad Arif; Jianshe Wei; Qi Zhang; Fei Liu; Gustavo Basurto-Islas; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  J Biol Chem       Date:  2014-08-15       Impact factor: 5.157

5.  Capping motifs stabilize the leucine-rich repeat protein PP32 and rigidify adjacent repeats.

Authors:  Thuy P Dao; Ananya Majumdar; Doug Barrick
Journal:  Protein Sci       Date:  2014-04-15       Impact factor: 6.725

6.  Myeloid-Specific Gene Deletion of Protein Phosphatase 2A Magnifies MyD88- and TRIF-Dependent Inflammation following Endotoxin Challenge.

Authors:  Lei Sun; Tiffany T Pham; Timothy T Cornell; Kelli L McDonough; Walker M McHugh; Neal B Blatt; Mary K Dahmer; Thomas P Shanley
Journal:  J Immunol       Date:  2016-11-21       Impact factor: 5.422

Review 7.  Tau Proteins and Tauopathies in Alzheimer's Disease.

Authors:  Fong Ping Chong; Khuen Yen Ng; Rhun Yian Koh; Soi Moi Chye
Journal:  Cell Mol Neurobiol       Date:  2018-01-03       Impact factor: 5.046

Review 8.  Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer's disease from a ferroptosis perspective.

Authors:  Paul J Derry; Muralidhar L Hegde; George R Jackson; Rakez Kayed; James M Tour; Ah-Lim Tsai; Thomas A Kent
Journal:  Prog Neurobiol       Date:  2019-10-08       Impact factor: 11.685

Review 9.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

10.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.